X
[{"orgOrder":0,"company":"Cordis","sponsor":"MedAlliance","pharmaFlowCategory":"D","amount":"$1,135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cordis Announces Acquisition of MedAlliance","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Cordis
Filters
Companies By Therapeutic Area
Details:
By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.
Lead Product(s):
Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Selution SLR
Highest Development Status: Approved
Product Type: Small molecule
Recipient:
MedAlliance
Deal Size: $1,135.0 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
October 18, 2022